Recent Quotes
My Watchlist
Indicators
Local Stocks
Local Stocks
Energy Stocks
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

Bellicum Pharma Comm (NQ: BLCM )

4.370 USD -0.100 (-2.24%)
Official Closing Price Updated: 4:22 PM EST, Feb 26, 2021 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press releases about Bellicum Pharma Comm

< Previous 1 2 3 4 5 6 7 Next >
Bellicum Reports Third Quarter 2017 Financial Results
Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers and orphan inherited blood disorders, today reported financial results for... 
From GlobeNewswire News Releases
Bellicum Announces Data Presentations on Lead Product Candidate BPX-501 and CAR-T Program at the 59th American Society of Hematology Annual Meeting
Four abstracts accepted, including oral presentation on BPX-501 
From GlobeNewswire News Releases
Bellicum Pharmaceuticals to Present at Three Healthcare Investor Conferences in September
Bellicum Pharmaceuticals, Inc. (Nasdaq:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers and orphan inherited blood disorders, today announced that senior... 
From GlobeNewswire News Releases
Today's Research Report Coverage on Biotech Stocks -- Bellicum Pharma, Cara Therapeutics, Cerus, and Coherus Biosciences
From PR Newswire
Bellicum Pharmaceuticals Reports Second Quarter 2017 Financial Results and Provides Corporate Update
Bellicum Pharmaceuticals, Inc. (Nasdaq:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers and orphan inherited blood disorders, today reported financial results for... 
From GlobeNewswire News Releases
Bellicum Pharmaceuticals Appoints Gregory Naeve as Chief Business Officer
Bellicum Pharmaceuticals, Inc. (Nasdaq:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers and orphan inherited blood disorders, today announced that Gregory Naeve,... 
From GlobeNewswire News Releases
Bellicum Pharmaceuticals to Report Second Quarter 2017 Financial Results and Host Conference Call and Webcast on August 8, 2017
Bellicum Pharmaceuticals, Inc. (Nasdaq:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers and orphan inherited blood disorders, today announced that the Company will... 
From GlobeNewswire News Releases
Bellicum Reports Clinical Results of BPX-501 in Pediatric Leukemias at the 22nd Congress of the European Hematology Association
Oral presentation highlights high success rate of haploidentical transplants, with low incidence of disease relapse and uncontrolled GvHD 
From GlobeNewswire News Releases
Bellicum Announces Clinical Data on BPX-501 at Presidential Symposium of the 22nd Congress of the European Hematology Association
U.S. and E.U. data suggest favorable outcomes to alternative transplants in patients with hematologic cancers and genetic blood diseases 
From GlobeNewswire News Releases
Research Reports Coverage on Biotech Stocks -- Achaogen, Bellicum Pharma, Coherus BioSciences, and Conatus Pharma
From PR Newswire
Bellicum Pharmaceuticals to Present at the Jefferies 2017 Global Healthcare Conference
Bellicum Pharmaceuticals, Inc. (Nasdaq:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers and orphan inherited blood disorders, today announced that Rick Fair,... 
From GlobeNewswire News Releases
Bellicum Announces Clinical Presentations at the 22nd Congress of the European Hematology Association
Bellicum Pharmaceuticals, Inc. (Nasdaq:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers and orphan inherited blood disorders, today announced that three abstracts... 
From GlobeNewswire News Releases
Bellicum Pharmaceuticals Announces Management Changes
Bellicum Pharmaceuticals, Inc. (Nasdaq:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers and orphan inherited blood disorders, today announced that Annemarie... 
From GlobeNewswire News Releases
Bellicum Pharmaceuticals Reports First Quarter 2017 Financial Results
Bellicum Pharmaceuticals, Inc. (Nasdaq:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers and orphan inherited blood disorders, today reported financial results for... 
From GlobeNewswire News Releases
Bellicum Pharmaceuticals to Present at the Deutsche Bank 42nd Annual Health Care Conference
Bellicum Pharmaceuticals, Inc. (Nasdaq:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers and orphan inherited blood disorders, today announced that Rick Fair,... 
From GlobeNewswire News Releases
Positive News in the Fight Against Cancer Fuels Quest for More Good Tidings
NetworkNewsWire Editorial Coverage 
From PR Newswire
How These Biotech Stocks are Faring? -- FibroGen, Bellicum Pharma, Intercept Pharma, and Cellect Biotechnology
From PR Newswire
New Clinical Trial Review: Leukemia Patients Treated by Bellicum Pharmaceuticals -- 91% remission, 94% Survival (median follow-up 301 Days) Source: Pluvia Research
Tags Industry: Human Impact Verticals Business: Finances and Investment Health: General
From PRWeb
Bellicum Pharmaceuticals Announces Late-Breaking Presentation of Dual-Switch CAR-T / TCR Technology at AACR
Bellicum Pharmaceuticals, Inc. (Nasdaq:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers and orphan inherited blood disorders, today announced two presentations of... 
From GlobeNewswire News Releases
Bellicum Pharmaceuticals Announces Closing of Public Offering
Bellicum Pharmaceuticals, Inc. (Nasdaq:BLCM) today announced the closing, on March 29, 2017, of its previously announced underwritten public offering of 5,750,000 shares of its common stock, including... 
From GlobeNewswire News Releases
Bellicum Pharmaceuticals Announces Pricing of Public Offering of Common Stock
Bellicum Pharmaceuticals, Inc. (Nasdaq:BLCM) today announced the pricing of an underwritten public offering of 5,000,000 shares of its common stock at a price to the public of $12.00 per share. The... 
From GlobeNewswire News Releases
Bellicum Pharmaceuticals Announces Proposed Public Offering of Common Stock
Bellicum Pharmaceuticals, Inc. (Nasdaq:BLCM) today announced that it has commenced an underwritten public offering of 5,000,000 shares of its common stock. Bellicum expects to grant the underwriters of... 
From GlobeNewswire News Releases
Bellicum Pharmaceuticals Provides Operational Update and Reports Financial Results for the Fourth Quarter and Year Ended December 31, 2016
Bellicum Pharmaceuticals, Inc. (Nasdaq:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers and orphan inherited blood disorders, today reported financial results for... 
From GlobeNewswire News Releases
Bellicum Pharmaceuticals to Present at the Barclays Global Healthcare Conference
Bellicum Pharmaceuticals, Inc. (Nasdaq:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers and orphan inherited blood disorders, today announced that Rick Fair,... 
From GlobeNewswire News Releases
Bellicum to Report Fourth Quarter and Full Year 2016 Financial Results and Host Conference Call and Webcast on March 13, 2017
Bellicum Pharmaceuticals, Inc. (Nasdaq:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers and orphan inherited blood disorders, today announced that the Company will... 
From GlobeNewswire News Releases
Bellicum Presents Updated Clinical Results at 2017 BMT Tandem Meetings on BPX-501 in Orphan Inherited Blood Disorders and Hematologic Cancers
Study demonstrates consistent, durable outcomes at six and 12 months with very low incidence of GvHD 
From GlobeNewswire News Releases
Bellicum Announces Initiation of Patient Dosing with Controllable CAR T-Cell Product Candidate
BPX-601 being studied in pancreatic cancers expressing PSCA 
From GlobeNewswire News Releases
Bellicum Announces Appointment of Rick Fair as Chief Executive Officer in Preparation for Commercialization of BPX-501 and Next Phase of Growth
Bellicum Pharmaceuticals, Inc. (Nasdaq:BLCM), a clinical stage biopharmaceutical company focused on discovering and developing novel cellular immunotherapies for cancers and orphan inherited blood... 
From GlobeNewswire News Releases
Adaptimmune and Bellicum Pharmaceuticals Enter a Strategic Collaboration to Evaluate Next-Generation T-Cell Therapies
Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, and Bellicum Pharmaceuticals, Inc. (Nasdaq:BLCM), a leader in developing novel, controllable cellular... 
From GlobeNewswire News Releases
Bellicum Presents Clinical Results to Date of BPX-501 Pediatric Program and Provides Regulatory Update at Investor Event During ASH Annual Meeting
Bellicum Pharmaceuticals, Inc. (Nasdaq:BLCM), a clinical stage biopharmaceutical company focused on discovering and developing novel cellular immunotherapies for cancers and orphan inherited blood... 
From Business Wire News Releases
< Previous 1 2 3 4 5 6 7 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.